ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides Difficile Infection

Guideline Topline

The 2021 American College of Gastroenterology guidelines on management of C. difficile reflect an expanding body of evidence for preventing, diagnosing, and treating the dangerous infection.

A Patient Care Online Guideline Topline

New 2021 guidelines from the American College of Gastroenterology (ACG) on the management of Clostridioides difficile infection (CDI) include recommendations that draw on a range of developments from increased recognition of challenges in diagnosis to the availability of biologic agents and the growing body of evidence to support use of fecal microbiota transplantation (FMT) in recurrent infection and in inflammatory bowel disease (IBD).

The guidelines, published in June 2021 in The American Journal of Gastroenterology, complement newly revised guidelines from the Infectious Disease Society of America (IDSA) and Society of Healthcare Epidemiologists of America (SHEA), according to ACG guideline authors. While the ACG guidelines match categories of infection severity with IDSA/SHEA, ie, non-severe, severe, and fulminant, the new recommendations focus principally on evidence-based, clinically relevant recommendations for the diagnosis, management, and prevention of CDI. The new content expands on areas inducing distinguishing C. difficile colonization from active infection and evaluation and treatment of CDI in the setting of IBD.  

Specific ACG recommendations follow in our Guideline Topline slide show summary.